CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology

19 May 2023
www.reuters.com
VaccinePatent InfringementmRNA
[1/3] A vial labelled "CureVac COVID-19 VaccineCOVID-19 Vaccine" is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration
May 19 (Reuters) - CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc (PFE.N) and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial.
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents.
In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccineCOVID-19 vaccine.
The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.
Pfizer and BioNTech did not immediately respond to requests for comment.
Pfizer and BioNTech in response had filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by CureVac.
The companies have previously told the court that their COVID vaccine Comirnaty does not work in the same way as CureVac's patented technology.
Pfizer and BioNTech are also facing patent infringement lawsuits from other companies.
Our Standards: The Thomson Reuters Trust Principles.
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Preview
Source: Reuters
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Preview
Source: Reuters
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Preview
Source: Reuters
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Preview
Source: Reuters
CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
Preview
Source: Reuters
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.